Completed PHASE3 INTERVENTIONAL 1-arm NCT00926952

Short Incubation Methylaminolevulinate Photodynamic Therapy Without Occlusion

Safety and Efficacy of Photodynamic Therapy With Short Incubation Methylaminolevulinate Without Occlusion in the Treatment of Actinic Keratoses.

Sponsor: Galderma Canada

Conditions Actinic Keratosis

Interventions Methylaminolevulinate (Metvix, Metvixia) Photodynamic Therapy (Aktilite)

Updated 7 times since 2017 Last updated: Sep 1, 2011 Started: Jul 31, 2009 Primary completion: Dec 31, 2010 Completion: Jan 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Actinic Keratosis and is currently completed. Galderma Canada leads this study, which shows 7 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3
Jan 2021 — Dec 2022 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Galderma Canada
Innovaderm Research Inc.

Data source: Innovaderm Research Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montreal, Canada